This is the monthly newsletter on public affairs sent by ESTRO to national societies
This is the ESTRO Public Affairs newsletter: a monitoring service offered by ESTRO to national societies of the radiation oncology area to keep up-to-date with oncopolicy issues.
This issue of the newsletter is dedicated to "What next for the oncology community after the EU elections?" 
Focus of the Month
What next for the oncology community after the EU elections? 
Happening Across Europe at a Glance

Other News
  • Cross-boarder healthcare in Europe
  • The WHO resolution on drug transparency 
  • The OECD releases new report on "Addressing problematic Opioid use in OECD countries"
  • EURODIS calls for holistic care for people living with rare diseases in Europe by 2030
  • Calls for Proposals 
What next for the oncology community after the EU elections?

Though the EPP (Group of the European Peoples' Party (Christian Democrats) remains with the largest number of seats. Yet, it is fairly reduced with parties such as the Green and the Liberals having a greater say in the decision-making process at the Parliamentary level.  It means that the two groups that have been setting the scene over the last years, EPP and Socialists and Democrats, will no longer be in the driving seat. Consequently, if the EPP would like to keep the importance placed on cancer they will have to push for this together with other parties.

Overview of what’s interesting for the oncology community in a nutshell.

  • Romania EPP MEP Adiana-Ioana Valean, who is the most recent chair of the ENVI committee (Environment, Public Health and Food Safety) is returning to the parliament
  • The Dutch MEP Bas Eickhout, lead candidate the Greens in the European elections already took a position on the need to put an end to endocrine disruptors and called for a deep role for the EC on key health priorities, such as access to medicines and hormone-disrupting chemicals
  • MEP champions on the medical device regulations such as German EPP MEP Peter Liese and Croatian S&D MEP Bilijana Borzana are returning

 MEPs whose presence will be missed include:

·         Slovenian EPP MEP Alojz Peterle, also president of the MEPs Against Cancer Group, and Belgian ALDE MEP Lieve – Wierinck have not been re-elected, who have both been driving voices for more research funding, the launch of the European cancer plan and the repurposing of drugs for cancer treatment.

·         Portuguese EPP MEPP Jose Inacion Faria and Czech S&D MEP Pavel Poc, both significant contributors to cancer treatment and hormone-disrupting chemicals.

·         The health technology assessment legislation has lost the lead rapporteur, Spanish Socialist MEP Soledad Caberzon Ruiz

Negotiations will continue in the month of June and a full list of MEPs on key committees is due on the 4th of July in Strasbourg.

The European Parliament 2019 

"The challenges in Peadiatric oncology are as diverse as the children and young people who are diagnosed with cancer. The unique landscape means that multiple stakeholders addressing the entire pathway of patient care have to work together for the better outcomes for patients. Such firm and committed partnerships over the last 20 years have enabled us to make progress iin peadiatric oncology. Working together on cross-discipline collaborations is at the heart of improving outcomes for childhood cancer"

- Professor Pamela Kearns, President of the European Society for Peadiatric Oncology (SIOP Europe)
First SIOPE annual meeting 20-24 May 2019 

FINLAND >>  the Finnish EU presidency goes live and it is the first to take up a 5-year strategic agenda Read more here

FRANCE >> wants to stop reimbursement of homeopathic medicines Read more here

IRELAND >> recalls over 150 medical devices annually. In 2017 there were 519 safety actions notified by the Irish
Health Products Regulatory manufacturers
Read more here

POLAND >> The Polish government is considering adopting new rules that would hide information and results of the price negotiations with pharma companies from the general public Read more here

ROMANIA and access to medicines across  the EU Member States >> following the request for a response to the  shortage of  basic oncology drugs in Romania,  EU experts explained that an agreement was signed in May 2018 where with a view of enforcing the obligation of continuous  supply across Member States Read more here

If the UK does leave at the end of October and the EP reverts its' revised size of 705 MEPs, the winners will be France and Spain each gaining 5 seats. Read more here

Cross-border healthcare in Europe

On 4 June, the European Court of Auditors published the outcomes of an audit of cross-border healthcare agreement sin the EU. It showed that the EU patients still do not benefits from the actions envisaged by the EU directive with only a majority of citizens aware if their rights to access medical care abroad.  The audit is based on visits to Denmark, Sweden, the Netherlands, Italy and Lithuania. 

Read more

The WHO resolution on drug transparency 

On 20 May, Italy submitted a new draft of its resolution on medicine cost and pricing transparency to the World Health Organisation Assembly showing that Italy is willing to make constructive achievements in the transparency initiative despite complaints from other EU countries.  While cost and clinical trial transparency are the key priorities of the original revised text for the transparency resolution and will guide the next WHO negotiation process, a few countries still oppose the resolution. Read more here

On 28 May the WHO panel assembly adopted a compromise resolution.

The OECD releases new report on
"Addressing problematic Opioid use in OECD countries"

An increase in prescription and over prescription of opioids for pain management is one of the main driving factors of the dilemma. The report depicts the opioid crisis as a complex public health issue that requires a cross sector approach including better information for patients and health care practitioners when dealing with pain management treatment.
The most pronounced increase has been observed in the United States, Canada, Sweden, Norway, Ireland, and England & Wales.

Read more
EURODIS calls for holistic care for people living with rare diseases in Europe by 2030  

Over 200 representatives of people living with a rare disease met in Bucharest  in May to discuss the results and implications of the newly-published p position paper "Achieving Holistic Person-Centered Care to Leave no One Behind."  The ambition is to maximise access to care, treatment, education, employment and psychological support for 30 million peoples with rare diseases, and their families by 2030.  

Read more

Calls for Proposals 
IMI2 – Calls 18 & 19: updated topic texts published deadline 26 June 

Future topics:  
Call 18: two-stage
Central repository of digital pathology slides to support the development of artificial intelligence tools
Supporting the development of engineered T cells
Accelerating research & innovation for advanced therapy medicinal products
Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials
Improving patient access, understanding and adherence to healthcare information: an integrated digital health information project
Call 19: a single-stage restricted call designed for existing successful IMI consortia

For more information on the calls visit the IMI website or sign-up to the webinars from 14 -26 June

MSCA-IF-GF Global Fellowships in the area of research and innovation: Deadline 11 September 
RIA Research and Innovation action: Improving low-dose radiation risk appraisal in medicine deadline 25 September 2019
CSA Coordination and support action: Research roadmap for medical applications of ionising radiation deadline: 25 September 2019

RIA Research and Innovation action: Further integrating Radiation Protection research in the EU deadline: 25 September 2019
CSA Coordination and support action: Optimised use of European research reactors deadline: 25 September 2019
RIA Research and Innovation action: Optimised fuels for production of medical radioisotopes deadline: 25 September 2019

For a list calls on the topics under the Euratom Research and Training Programme click
If you have any questions  please contact Gabriella Axelsson
ESTRO Public Affairs Project Manager
Copyright © 2019 ESTRO, All rights reserved.

unsubscribe from this list    update subscription preferences